Buy The Rumor: Allergan Goes Public on Divestiture, Acquisition PlansMark Melin
The inside story at Allergan is now firmly public, as the company’s plans to divest itself of certain product categories and acquire another firm were confirmed over the weekend.
What was rumored has become fact
This weekend Allergan publicly confirmed it will shed the firm's generic-drug business to Teva Pharmaceuticals for $40.5 billion and the company will purchase Naurex, a developer of antidepressant drugs, for $560 million.
On July 22 ValueWalk reported on a secret . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.